In the last twelve months the UK’s prospects have improved significantly thanks to December’s trade deal with the EU and strong progress with the Covid-19 vaccinations programme. In our view there is around 15% GDP growth available over the next two years. The revival in sentiment towards the UK has been particularly good news for the small- and mid-cap areas that form the lion’s share of our portfolio.
The UK overall still looks cheap in absolute and relative terms, with markets enjoying a text-book recovery as the safer large-cap companies rise. Laggards tend to be the small-cap firms, which are less well researched.
Our TM CRUX UK Special Situations Fund seeks out companies of all sizes where ongoing changes can result in improving share prices. Such changes could include product launches, new management, business strategy, or a company moving its stockmarket listing to another city.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Aviva gets its act together
Insurance conglomerate Aviva (LSE: AV.)was best avoided for many years, as the corporate narrative of selling divisions to improve the shareholder’s lot had not been matched by actions. But that changed last September with the arrival of new CEO Amanda Blanc and the promise to focus on the UK, Canada and Irish subsidiaries being fulfilled. Already divisions in Singapore, France, Italy, Turkey and Poland have been sold, raising £8bn. The shares have had a good run and now yield only a little over 5%. Further upside comes from our belief in the potential for management to deliver up to 80p per share from disposal proceeds back to shareholders, which takes the effective yield closer to 7%.
Ready for a state spending spree
A medium-sized firm we like is Hill & Smith (LSE: HILS). The company makes worthy but essential items for infrastructure markets such as highways and utilities; products range from road message boards to cooling towers. Hill & Smith is well positioned for increased infrastructure spending on roads, railways and energy distribution by both the UK and US governments. We are particularly encouraged by the arrival of Paul Simmons from Halma as Group CEO.
At Halma Simmons was part of a strong shareholder-friendly culture undertaking multiple acquisitions, culminating with the shares becoming some of the most highly valued on the UK market. Initial signs are promising. If Simmons can transfer some of the “Halma magic” to Hill & Smith, and with the shares at a significantly lower valuation, it will provide scope for strong share-price performance over the next few years.
Scooping up software
Finally, small-cap AdvancedAdvT (LSE: ADVT) is a very new company, formed by established software entrepreneur Vin Murria OBE with an investment strategy of seeking mid-cap acquisition opportunities in the software sector. Murria has had three previous successes in the UK stockmarket where software businesses were acquired and improved, leading to healthy increases for shareholders in each case.
We expect AdvancedAdvT to acquire a profitable software business with subsequent improvements made to the operational performance. Murria has invested £17.5m in the company and we share her confidence that Advanced ADvT will be another success.
-
8 of the best houses for sale with annexesThe best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
-
Zelenskyy moves to appease Donald Trump – what happens now?Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
-
Rolls-Royce stock jumps 15% – could it climb further?Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
-
The power of private marketsInterview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success
-
Global investors have overlooked these top tips in emerging marketsOpinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
-
King Coal has not been dethroned yet — should you buy?The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
-
It’s time to start buying Europe again, says Merryn Somerset WebbOpinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fadesFood-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
-
Should investors stay bullish and buy UK and US stocks?Opinion Ignore the Eeyores, says Max King. The outlook for stocks in both Britain and America remains auspicious
